Patents Assigned to The University of Chicago
-
Publication number: 20250052960Abstract: Systems and methods for generating and manipulating a guided electromagnetic wave in a waveguide are provided. The optical system includes a waveguide, such as a two-dimensional waveguide, and an optical element disposed adjacent the surface of the waveguide. To generate the guided electromagnetic wave, a converging laser beam is generated and coupled to the waveguide by steering the converging laser beam towards an edge of the waveguide and with a beam center trajectory approximately parallel to a surface of the waveguide.Type: ApplicationFiled: August 8, 2024Publication date: February 13, 2025Applicant: The University of ChicagoInventors: Jiwoong Park, Hanyu Hong, Myungjae Lee
-
Patent number: 12216121Abstract: Described herein are nucleic acid molecules and complexes useful for spatiotemporally mapping intra-endosmal thiol disulphide exchange. Aspects of the disclosure relate to a composition comprising a first nucleic acid conjugated to a normalization moiety; and a second nucleic acid conjugated to a catalytic substrate; wherein reaction of the substrate with a catalyst produces a detectable product; and wherein the first and second nucleic acids are complementary or substantially complementary. Further aspects relate to a composition comprising: a first nucleic acid conjugated to a normalization moiety and to a catalytic substrate; and a second nucleic acid; wherein reaction of the substrate with a catalyst produces a detectable product; and wherein the first and second nucleic acids are complementary or substantially complementary.Type: GrantFiled: April 12, 2018Date of Patent: February 4, 2025Assignee: THE UNIVERSITY OF CHICAGOInventors: Yamuna Krishnan, Krishna Dan, Aneesh T. Veetil, Kasturi Chakraborty
-
Patent number: 12210935Abstract: Technologies for resource-efficient quantum error correction are disclosed. A quantum computer may include physical gate qubits, capable of general quantum gate operations such as single-qubit operations and nearest-neighbor two-qubit operations. Each physical qubit gate may be controllably coupled to a quantum memory. The quantum memory may have a lower per-gate error rate than the physical qubit gates as well as a lower per-qubit cost. Because errors accrue at a lower rate in the quantum memory, the physical gate qubits may be able to perform error correction for a large number of logical qubits in the quantum memory, even if the physical gate qubits have an error rate relatively close to an error threshold.Type: GrantFiled: March 3, 2020Date of Patent: January 28, 2025Assignee: THE UNIVERSITY OF CHICAGOInventors: David Schuster, Srivatsan Chakram
-
Patent number: 12209143Abstract: The present disclosure provides macrocyclic and macrobicyclic peptides with secondary structures that are stabilized over the corresponding non-cyclic peptides. The macrocyclic and macrobicyclic peptides are formed from peptides with adduct-forming, complementary reactive side chain moieties.Type: GrantFiled: April 9, 2020Date of Patent: January 28, 2025Assignee: THE UNIVERSITY OF CHICAGOInventors: Raymond E. Moellering, Jeffrey E. Montgomery
-
Publication number: 20250026814Abstract: Here, the inventors report that natural WT SARS-CoV-2 infection induces memory B cells expressing potently neutralizing antibodies against VOCs. Moreover, natural WT infection largely induced antibodies against spike epitopes outside of the RBD, most of which were non-neutralizing against WT and VOCs. Additionally. RBD-binding antibodies could be categorized into 3 distinct classes based on their binding profiles against RBD mutant constructs. The inventors identified VOC-neutralizing antibodies against three distinct regions of the spike protein, including the two epitopes on the RBD and one epitope in the NTD. Together, this study identifies that natural WT infection induces memory B cells that can produce neutralizing antibodies against recent SARS-CoV-2 VOCs and have the potential to be recalled by vaccination.Type: ApplicationFiled: November 16, 2022Publication date: January 23, 2025Applicant: THE UNIVERSITY OF CHICAGOInventors: Patrick WILSON, Siriruk CHANGROB, Haley DUGAN, Christopher STAMPER
-
Publication number: 20250025542Abstract: Aspects of the present disclosure are directed to methods and compositions for generation of antigen-specific regulatory T cells. Certain aspects relate to methods and compositions for generating tolerogenic antigen presenting cells, including tolerogenic dendritic cells. The present disclosure includes compositions, including nanocarrier compositions, comprising TLR agonists, and immunosuppressive agents and optionally an antigen. Also disclosed are methods for use of such compositions in generation of tolerogenic antigen presenting cells and treatment of certain conditions, including autoimmune and inflammatory conditions.Type: ApplicationFiled: November 9, 2022Publication date: January 23, 2025Applicant: THE UNIVERSITY OF CHICAGOInventors: Aaron ESSER-KAHN, Peter DEAK
-
Publication number: 20250018038Abstract: Aspects of the present disclosure are directed to survivin-targeting polypeptides, including antibodies, antibody-drug conjugates, antibody fragments, antibody-like molecules, and chimeric receptors. Also disclosed herein are nucleic acids encoding for such survivin-targeting polypeptides and cells comprising such nucleic acids. Described are methods for detection, diagnosis, and treatment of cancer using survivin-targeting polypeptides.Type: ApplicationFiled: October 6, 2022Publication date: January 16, 2025Applicant: THE UNIVERSITY OF CHICAGOInventors: Anthony KOSSIAKOFF, Annika SÄÄF, Marcin URA, Somnath MUKHERJEE
-
Publication number: 20250017898Abstract: Embodiments are directed to a series of novel small molecule activators of NRF2 dependent gene expression that are evaluated in an effort to develop therapeutic methods against diseases with deregulated KEAP1-NRF2 signaling.Type: ApplicationFiled: June 11, 2024Publication date: January 16, 2025Applicant: THE UNIVERSITY OF CHICAGOInventors: Raymond MOELLERING, John COUKOS, Gihoon LEE, Jae Won CHANG, Gokhan MUTLU
-
Patent number: 12186402Abstract: Provided herein are polymer materials that find use in, for example, delivery of short-chain fatty acids. In particular, polymers are provided that form stable nanoscale structures and release their payload, for example, by cleavage of a covalent bond (e.g., via hydrolysis or enzymatic cleavage). The polymers are useful, for example, for delivery of payloads (e.g., SCFAs) to the intestine for applications in health and treatment of disease, and have broad applicability in diseases linked to changes in the human microbiota including inflammatory, autoimmune, allergic, metabolic, and central nervous system diseases, among others.Type: GrantFiled: April 19, 2023Date of Patent: January 7, 2025Assignee: The University of ChicagoInventors: Jeffrey A. Hubbell, Ruyi Wang, D. Scott Wilson, Cathryn R. Nagler, Catherine Plunkett
-
Patent number: 12188084Abstract: Methods, compositions and kits are provided to amplify an amount of genomic methylated DNA that can be subsequently analyzed and/or sequenced. It has particular use with small amounts of DNA, including, but not limited to cell free DNA samples. In some embodiments, the ratio of polymerase and methyltransferase is controlled in order to provide maximum yields. In some embodiments, a dual primase/polymerase is used.Type: GrantFiled: September 27, 2021Date of Patent: January 7, 2025Assignee: The University of ChicagoInventors: Chuan He, Boxuan Simen Zhao, Pradnya Narkhede, Chang Liu, Xiaolong Cui
-
Patent number: 12180267Abstract: Provided herein are anti-neuraminidase agents useful for neutralization of influenza virus infection, and methods of use and manufacture thereof. In particular, compositions comprising anti-neuraminidase agents (e.g., antibodies) that are cross-reactive with multiple influenza strains are provided, as well as methods of treatment and prevention of influenza infection therewith.Type: GrantFiled: June 15, 2023Date of Patent: December 31, 2024Assignee: The University of ChicagoInventors: Patrick Wilson, Yaoqing Chen, Haley L. Dugan
-
Patent number: 12174225Abstract: Methods and systems are disclosed for sensing an environment electric field. In one exemplary implementation, a method includes disposing a sensor in the environment, wherein the sensor comprising a crystalline lattice and at least one optically-active defect in the crystalline lattice; pre-exciting the crystalline lattice to prepare at least one defect in a first charge state using a first optical beam at a first optical wavelength; converting at least one defect from the first charge state to a second charge state using a second optical beam at a second optical wavelength; monitoring a characteristics of photoluminescence emitted from the defect during or after the conversion of the at least one defect from the first charge state to the second charge state; and determining a characteristics of the electric field in the environment according to the monitored characteristics of the photoluminescence.Type: GrantFiled: January 24, 2023Date of Patent: December 24, 2024Assignee: The University of ChicagoInventors: Gary Wolfowicz, Samuel James Whiteley, David Daniel Awschalom
-
Publication number: 20240417802Abstract: The current disclosure provides for novel therapeutic methods by identifying patient populations that may be treated effectively by immunotherapies. Accordingly, aspects of the disclosure relate to a method for treating cancer in a subject comprising administering to the subject an immunotherapy after a biological sample from the subject has been analyzed for membrane-localized antigens (mAg).Type: ApplicationFiled: October 14, 2022Publication date: December 19, 2024Applicant: THE UNIVERSITY OF CHICAGOInventors: Jeffrey HUBBELL, Priscilla BRIQUEZ, Zoe GOLDBERGER, Sylvie HAUERT
-
Publication number: 20240415851Abstract: Disclosed herein is a class of molecules termed remodilins that inhibit serum response factor (SRF). By inhibiting SRF, a number of downstream pathways can be targeted. The remodilins can be used to treat glaucoma, inhibit tumor cell growth, inhibit tumor metastasis, inhibit hypoxia-induced response, and/or reduce cellular metabolism.Type: ApplicationFiled: March 14, 2024Publication date: December 19, 2024Applicants: The University of Chicago, The United States of America, as Represented by the Secretary, Department of Health and Human, President and Fellows of Harvard College, IIT Research Institute, Beth Israel Deaconess Medical Center, Inc.Inventors: Julian SOLWAY, Nickolai DULIN, Marsha ROSNER, Gokhan MUTLU, Diane LUCI, David MALONEY, Chan Young PARK, Jeffrey FREDBERG, David MCCORMICK, Ramaswamy KRISHNAN
-
Publication number: 20240408138Abstract: Aspects of the present disclosure are directed to INCENP-targeting polypeptides, including antibodies, antibody-drug conjugates, antibody fragments, antibody-like molecules, and chimeric receptors. Also disclosed herein are nucleic acids encoding for such INCENP-targeting polypeptides and cells comprising such nucleic acids. Described are methods for detection, diagnosis, and treatment of cancer using INCENP-targeting polypeptides.Type: ApplicationFiled: October 6, 2022Publication date: December 12, 2024Applicant: THE UNIVERSITY OF CHICAGOInventors: Anthony KOSSIAKOFF, Annika SÄÄF, Marcin URA, Somnath MUKHERJEE
-
Publication number: 20240410901Abstract: The current disclosure describes light switchable actin binding protein (ABP) built from a photosensitive protein and an ABP. This is accomplished by creating an ABP that is caged and has a weak affinity to actin in the dark and uncaged with a strong affinity for actin in the light. These light-switchable polypeptides can recruit other actin binding proteins of interest to actin filaments spatiotemporally and reversibly. Aspects of the disclosure relate to polypeptides that are useful for labeling actin fibers. Accordingly, the disclosure relates to a polypeptide comprising the amino acid sequence: AXXIXXXA(M)nGVADLIKKFE(X?)n? (SEQ ID NO:1) or an amino acid sequence with at least 80% sequence identity to SEQ ID NO:1, wherein X is any amino acid, n and n? are each independently selected from 0 and 1, and X? is equal to SISKEE.Type: ApplicationFiled: October 7, 2022Publication date: December 12, 2024Applicant: THE UNIVERSITY OF CHICAGOInventors: Tobin SOSNICK, Kourtney KROLL, Ronald ROCK, Alexander FRENCH
-
Publication number: 20240398785Abstract: The present disclosure provides methods and compositions for inducing trained immunity, preventing infections, improving immune responses, modulating the activity of at least one protein in the BCL family of proteins, increasing the efficacy of a vaccine, and reducing the risk of a secondary tumor in a subject diagnosed with a primary cancer.Type: ApplicationFiled: May 30, 2024Publication date: December 5, 2024Applicant: THE UNIVERSITY OF CHICAGOInventors: Aaron ESSER-KAHN, Hannah KNIGHT, Jainu AJIT
-
Publication number: 20240382591Abstract: The current disclosure provides for techniques and approaches for the generation of autologous mutant neoantigen-specific, TCR-engineered T cells used for adoptive transfer in treatment of cancer patients. Also provided are surrogate cancer cells, which is a personalized cell system that can be used for vaccination and TCR discovery in cancer patients.Type: ApplicationFiled: September 21, 2022Publication date: November 21, 2024Applicants: THE UNIVERSITY OF CHICAGO, CHARITÉ - UNIVERSITÄTSMEDIZIN BERLINInventors: Hans SCHREIBER, Matthias LEISEGANG, Steven Patrick WOLF, Vasiliki ANASTASOPOULOU, Karin SCHREIBER, Michael BISHOP, Amittha WICKREMA
-
Patent number: 12145991Abstract: A pharmaceutical composition generally includes a therapeutic antibody, or fragment thereof, and a pharmaceutically acceptable carrier. The therapeutic antibody specifically binds to a target peptide that mediates pain in a subject. The composition may be administered to a subject experiencing pain to at least partially alleviate the pain.Type: GrantFiled: November 1, 2019Date of Patent: November 19, 2024Assignees: UNM Rainforest Innovations, Loyola University of ChicagoInventors: Karin Westlund High, Ravi Venkata Durvasula, Adinarayana Kunamneni
-
Patent number: 12138320Abstract: Radioisotope-labeled small molecule activity-based probes that target the cancer associated serine hydrolase neutral cholesterol ester hydrolase 1 (NCEH1) are described. The probes can undergo a reaction with the NCEH1, resulting in covalent bonding of a portion of the probe molecule to the NCEH1. Also described are methods of labeling NCEH1 in biological samples, such as cells or tissue, and methods of visualizing tumors using the radioisotope-labeled NCEH1 probes as tracer compounds, either alone or in combination with assessing the efficacy of a cancer treatment or potential cancer treatment.Type: GrantFiled: May 11, 2021Date of Patent: November 12, 2024Assignee: The University of ChicagoInventors: Raymond E. Moellering, Jae Won Chang